Aligos Therapeutics Inc
5WK0
Company Profile
Business description
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
Contact
One Corporate Drive
2nd Floor
South San FranciscoCA94080
USAT: +1 800 466-6059
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
70
Stocks News & Analysis
stocks
Undervalued ASX share searches for cost savings
Cost savings from recent acquisition underpin our earnings growth forecasts.
stocks
Chart of the Week: Where we see opportunities after year end market sell-off
The latest insights from our equity research team.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,877.50 | 43.90 | -0.49% |
| CAC 40 | 8,022.69 | 29.82 | -0.37% |
| DAX 40 | 24,130.14 | 32.51 | -0.13% |
| Dow JONES (US) | 48,057.75 | 497.46 | 1.05% |
| FTSE 100 | 9,655.53 | 13.52 | 0.14% |
| HKSE | 25,529.76 | 11.02 | -0.04% |
| NASDAQ | 23,654.15 | 77.67 | 0.33% |
| Nikkei 225 | 50,195.61 | 407.19 | -0.80% |
| NZX 50 Index | 13,395.87 | 24.81 | 0.19% |
| S&P 500 | 6,886.68 | 46.17 | 0.67% |
| S&P/ASX 200 | 8,592.00 | 39.50 | -0.46% |
| SSE Composite Index | 3,874.86 | 25.63 | -0.66% |